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Age at diagnosis ofAIDS at this
hospital to October 1987
Age (years) No of patients
0-19 2
20-24 19
25-29 26
30-34 48
35-39 57
40-44 33
45-49 3 1
50-54 7
55-59 6
60-64 2
65 4
transbronchial biopsy did not show any pathogen. He
was treated with co-trimoxazole and hydrocortisone.
After 14 days of co-trimoxazole he had improved
clinically and radiographically and was discharged
receiving maintenance treatment.
Comment
Both these patients were positive for HIV antibody
and had a clinical and radiological presentation
suggestive of P carinni pneumonia that responded to
treatment; thus the criteria fbr a diagnosis of AIDS
were satisfied. ' In case 2 the diagnosis was complicated
by the previous amiodarone treatment, though
pneumonitis induced by amiodarone is unusual at a
daily dosage less than 400 mg.23 Chest infections are
common in the elderly. The increasing incidence of
HIV infection and a reluctance of older homosexuals to
admit to at risk behaviour may mean that elderly
patients will die without AIDS being diagnosed. In the
United States 10% of patients with AIDS are over 50,
2-5% over 60, and 0 4% over 70. The table shows the
age distribution of our patients with AIDS up to
October 1987. Six of 235 (2 5%) patients were over 60.
P carinii pneumonia should be considered in all
patients with atypical chest infections, even when there
are no apparent risk factors.
We thank Miss Linda Stannard for preparing the
manuscript and Dr D J R Morgan for his helpful comments.
I Anonymous. Revision of the CDC surveillance case definition for acquired
imrmlunodeficiency syndrome. .7AMA 1987;258:1143-54.
2 Marchinski FE, Lansten TS, Waxman HL, Josephson ME. Amiodarone
pulmonary toxicity. Ann Intern Med 1982;97:839-45.
3 Suarez LD, Poderoso IJ, Elsner B, Bunster AM, Esteva H, Bellotti M.
Subacute pneumopathy during amiodarone therapy. Chest 1983;83:566-8.
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Parkinsonism, tremor, and
depression induced by
cinnarizine and flunarizine
Dolors Capell, Joan-Ramon Laporte,
Josep-Maria Castel, Carmen Tristan,
Angeles Cos, Francisco Jose Morales-Olivas
Cinnarizine and flunarizine are piperazine derivatives
with antihistamine properties and calcium channel
blocking activity. Several recent reports have des-
cribed extrapyramidal reactions and depression
associated with their use.
Methods and results
In Spain a system of spontaneous reporting of
adverse drug reactions has been operating since
1983. Around 5000 reports have been received, of
which 86 refer to cinnarizine as the suspected drug,
25 to flunarizine, and five to both drugs taken
simultaneously. Of these 116 reports 87 described
extrapyramidal symptoms or depression, or both:
cinnarizine had been taken in 70 cases, flunarizine in
13, and both drugs in four.
Seventy patients developed tremor and parkin-
sonism while being treated with cinnarizine (see table).
They were not taking other drugs likely to induce
parkinsonism, except for three patients, one of whom
was also taking sulpiride, one thiethylperazine
and dimenhydrinate, and one thioridazine (he sub-
sequently recovered when cinnarizine was withdrawn
without stopping thioridazine). Eight additional
patients (two men, six women) presented with
parkinsonism and three men presented with tremor
while being treated with flunarizine (5 mg/day in one
patient and 10 mg/day in 10). Four other patients
developed parkinsonism (two men) or tremor (one
man, one woman) while treated simultaneously with
both drugs.
Four patients (two men, two women, aged 24 to 67)
presented with depression while taking flunarizine
(three patients, one of them also with tremor) or
cinnarizine (one patient, who also presented with
parkinsonism). The daily dose offlunarizine was 10 mg
and of cinnarizine 150 mg. The intervals between
starting drug treatment and the appearance of the first
symptoms ranged from two days (in this patient tremor
was also noted) to 10 months. The four patients
Characteristics of 70 patients with parkinsonism or tremor induced
by cinnarizine. Unless otherwise stated, results are numbers (and
percentages) ofpatients
Parkinsonism Tremor
No of patients: 39 31
Women* 24 20
Men* 13 11
Median age (range) (years) 78 (53-90) 68 (38-85)
Dose (mg):
<150 3 (8) 12 (39)
150 28 (72) 14 (45)
>150 6 (15) 5 (16)
Unknown 2 (5)
Induction period:
<l month 7(18) 6(19)
1-6 months 6(15) 6 (19)
6-12 months 6 (15) 10(32)
1-3 years 10(26) 5 (16)
>3 years 5(13) 0
Unknown 5 (13) 4 (13)
Recovered after withdrawal of drug:
Within 1st 3 months 13 (33) 17 (55)
In 3-6 months 9 (23) 0
In 6-18 months 2 (5) 1 (3)
Unknown 4(10) 5 (16)
Not within 1st 3 months 4(10) 6 (19)
Not in 3-6 months .> 1 (3) 0
Not in 6-12 months 1 (3) 0
Not in > I year 1 (3) 0
Unknown 4 (10) 2 (7)
*The sex of two patients with parkinsonism was unknown.
improved when treatment stopped; three of them
improved during the first month, but no exact
information was available about the fourth. None of
these patients were taking any other drug which could
have contributed to their depression.
Comment
In Spain cinnarizine is marketed in 10 pharma-
ceutical preparations, eight of which are fixed dose
combinations with other drugs. The most common
indications are cerebral and peripheral arterial
insufficiency. The top selling preparations contain
75 mg per tablet, and the recommended dose is 75 mg
twice a day. Approved indications for flunarizine are
the same as for cinnarizine. In the United Kingdom
cinnarizine is marketed as 15 mg tablets for vestibular
disorders and motion sickness, with a maximum
recommended dose of 30 mg three times a day.4 In
Spain 5-7% of the population over the age of 60 may be
receiving long term cinnarizine.5 The consumption of
flunarizine is also high: in 1986, 1-2 million units were
dispensed. Not surprisingly therefore a large number
of cases of extrapyramidal symptoms and depression
attributed to these drugs have been assembled by our
national scheme.
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As the table shows, parkinsonism can be induced
even by daily doses of cinnarizine of less than 150 mg.
Patients with tremor tended to be younger (Mann-
Whitney U test, p=0O0043), however, and seemed to
have taken lower cumulative doses than those with
parkinsonism (Mann-Whitney U test, p=0O0417).
Patients with flunarizine induced parkinsonism
(median age 63) were younger than those affected by
cinnarizine (median age 78) (Mann-Whitney U test,
p=00059), and these differences were apparently not
related to different indications for the use of each drug.
Cinnarizine and flunarizine are piperazine deriva-
tives structurally related to some phenothiazines, and
this may explain their extrapyramidal effects. Their
calcium channel blocking activity may also contribute
to this effect. We have started a case-control study with
the aim of quantifying the risk of extrapyramidal
disorders associated with these drugs.
1 Marti Mass6 JF, Carrera N, de la Puente E. Posible parkinsonismo por
cinaricina. Med Clin (Barc) 1985;85:614-6.
2 Chouza C, Scaramelli A, Caamauio JL, De Medina 0, Alianati R, Romero S.
Parkinsonism, tardive dyskinesia, akathisia, and depression induced by
flunarizine. Lancet 1986;i: 1303-4.
3 Meyboom RHB, Ferrari MD, Dieleman BP. Parkinsonism, tardive dyskinesia,
akathisia, and depression induced by flunarizine. Lancet 1986;ii:292.
4 Joint Formulary Committee. British national formulary number 14. London:
British Medical Association and The Pharmaceutical Society ofGreat Britain,
1987:160.
S Laporte JR, Capella D. Useless drugs are not placebos: lessons from flunarizine
and cinnarizine. Lancet 1986;ii:853-4.
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Dangerous oronasal obstruction
in weak senile patients
A M M Berkhout, H J M Cools
During routine surveillance in this 320 bed nursing
centre patients are sometimes found in a dangerous
condition of dyspnoea and cyanosis. We describe five
cases in which this condition was caused by oronasal
obstruction.
Case reports
Case I-An 85 year old woman with severe
Alzheimer's disease was emaciated, drank little, and
remained bedridden; she was receiving no drugs. She
was found in a dangerous dyspnoeic and cyanotic state;
the nostrils were sucked in during inspiration but a
certain degree of inspiration was audible. Attempts to
open the tightly closed mouth met with little success
and were repelled by the patient. There was a deviated
nasal septum swelling of the mucosa. A disposable
catheter (Charriere 12, 13 cm long) was inserted into
the smaller nostril. Dyspnoea and cyanosis resolved
within several minutes, at which time the patient
opened her mouth spontaneously. She had neither
teeth nor dentures. The nasal catheter was removed
several hours later. There was no recurrence.
Case 2-A 76 year old woman with severe
Alzheimer's disease was dehydrated and wasted; she
was receiving 50 mg pentazocine four times daily as an
analgesic. Years ago she had broken her nose. She was
found in bed in a highly dyspnoeic and cyanotic state.
Her toothless mouth was closed tightly and the nostrils
were sucked in. The nasal mucosa was swollen. A nasal
airway was introduced and the symptoms resolved
within five minutes.
Case 3-An 89 year old woman was transferred to
the nursing centre in a weak condition after having
been admitted with gastric haemorrhaging. One even-
ing she was found to be feverish and severely dyspnoeic
and cyanotic. The nostrils were sucked in during
inspiration and her toothless mouth was closed tightly.
Again a disposable catheter alleviated the obstruction.
The nasal septum was deviated and the mucosa was
swollen. She suffered three more episodes the same
night. Three days later she died ofbronchopneumonia.
Case 4-A 78 year old woman with heart failure,
extreme polyarthrosis, and a general loss of strength
was receiving frusemide, prazosin, haloperidol, and
promethazine (as a hypnotic). She remained bed-
ridden, ate poorly, and developed a decubitus ulcer.
Several days before her death she became cyanotic with
tightly closed toothless mouth and pinched in nostrils.
Nasal catarrh and a deviated nasal septum were found.
A nasal catheter was introduced but was removed by
the patient. The nose was taped so that the nostrils
could not be pulled inwards by suction; the patient did
not protest.
Case 5-An 88 year old woman who had suffered a
complete stroke was receiving digoxine and dytaurese.
In the past she had broken her nose. She had neither
teeth nor dentures. One week before her death she
developed a respiratory tract infection. She ate and
drank little and became bedridden. The next day she
suffered an episode similar to those experienced by the
patients in case 1-4. There was no recurrence. She died
of aspiration pneumonia.
Comment
Since 1984 five women in this centre have been
found suffering from dangerous oronasal obstruction:
a tightly closed mouth without teeth and dentures,
sucked in nostrils, a deviated nasal septum, and
swollen nasal mucosa. They were bedridden, cachec-
tic, and dehydrated but not unconscious. They did not
raise the alarm. Three of them were in a terminal
phase. Though a restrictive medical policy is followed
in such cases, the obstruction can easily be eliminated
with a disposable catheter.
Upper airway obstruction may occur when, in
addition to imperfect patency of the nose, inspiratory
suction is greater than the ability of the oropharyngeal
muscles to keep the mouth and throat open. In babies
with small upper airways this phenomenon can be
observed during sleep and can lead to their sudden
death2; factors other than suction within the nose,
mouth, and throat can also contribute to sudden infant
death.3 Weak senile patients can suffer this oronasal
obstruction even while awake if there is also a catarrhal
inflammation of the nose and a pre-existing deviated
nasal septum. Though the oral cavity is softer without
teeth or dentures, it is not clear why patients with
nasal obstruction do not breathe through the mouth.
The first patient (like the others usually a nasal
breather) did this on another occasion when her nose
was carefully blocked by pinching.
1 Klein M, Reynolds LG. Relief of sleep related oropharyngeal airway obstruc-
tion by continuous insufflation of the pharynx. Lancet 1986;i:935-9.
2 Guilleminault Ch, Heldt G, Powell N, Riley R. Small upper airway in near miss
sudden infant death syndrome infants and their families. Lancet 1986;i:402-7.
3 Milner AD. Recent theories on the cause of cot death. Br Med J 1987;295:
1366-8.
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